A Phase II study has shown that trastuzumab-DM1 (T-DM1) shrank tumours in one-third of women who had already taken seven medicines on average for advanced HER2-positive breast cancer.
The primary endpoint of the trial, which evaluated single-agent T-DM1 in 110 women, was a complete or partial tumour shrinkage of at least 30%, seen in two tumour assessments at least 28 days apart.
T-DM1 is an antibody-drug conjugate, which attaches trastuzumab and DM1 together using a stable linker that is capable of destroying cancer cells.
Low levels of platelets in the blood (7%), fatigue (5%) and cellulitis (4%) were the most common severe adverse events of using T-DM1, the study observed.
Swiss drugmaker Roche has licensed the technology for T-DM1 under an agreement with ImmunoGen and submitted a Biologics License Application for the drug to the US Food and Drug Administration.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData